An interventional study of Lubricin and Sodium Hyaluronate in Dry Eye Syndrome and Tear Film Insufficiency, sponsored by Dompé Farmaceutici S.p.A. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-26.
Sponsored by Dompé Farmaceutici S.p.A · Not applicable, Interventional, and Treatment
The objective of the clinical investigation was to evaluate tolerability, safety and efficacy of the tested medical device, eye drop containing Lubricin 150 µg/mL, as compared with a standard sodium hyaluronate 0.13% eye drop solution in subjects with moderate dry eye disease.
Primary objective:
Secondary objectives:
All parameters will be evaluated at screening visit, baseline (day 1), visit 3 (day 14±2) and visit 4 (day 28±4) and at follow-up (final visit) at least 7 days but not more than 9 days after the last treatment.
The results for both the SANDE questionnaire and adverse events are reported at the patient level, without distinguishing between Study Eye and Non-Study Eye. This approach reflects the overall condition and experiences of the patient rather than attributing outcomes to individual eyes.
The Study Eye was identified as the eye with the worst overall tolerability score at Visit 2 (Day 1).
This study is a multicenter, randomized, double-masked, controlled, non-inferiority study to evaluate tolerability, safety and efficacy of Lubricin eye drops versus sodium hyaluronate eye drops (Ocuyal®) administered four times a day for 4 weeks and 1 week follow-up in subjects with moderate dry eye.
1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.
This study's enrollment of 56 is close to the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.
Browse Dry Eye Syndromes studies →Dompé Farmaceutici S.p.A is the lead sponsor of 51 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
To be checked at the screening visit (V1) from day -14 to day -8 days before run-in period and confirmed at baseline visit (V2):
Exclusion Criteria:
Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:
Lubricin 150 µg/ml eye drops. The test investigational device as well as the comparator, was instilled q.i.d.(four times a day), one drop into each eye for 28±4 days. After the end of the treatment period, all the subjects used 0.13% Sodium hyaluronate eye drops (Ocuyal®) q.i.d. for the following 7-9 days. Before the start of the treatment (run-in period of 7 days), the subjects were allowed to use NaCl 0.9% ocular solution (Nebul®) q.i.d.
Device: Lubricin
Sodium hyaluronate 0.13% eye drops. The comparator, as well as the test investigational device, was instilled q.i.d.(four times a day), one drop into each eye for 28±4 days. After the end of the treatment period, all the subjects used 0.13% Sodium hyaluronate eye drops (Ocuyal®) q.i.d. for the following 7-9 days. Before the start of the treatment (run-in period of 7 days), the subjects were allowed to use NaCl 0.9% ocular solution (Nebul®) q.i.d.
Device: Sodium Hyaluronate
Lubricin 150 µg/ml eye drops
Sodium hyaluronate 0.13% eye drops
Also known as: Ocuyal®
Change From Baseline (V2) in Frequency and Severity of Dry Eye Symptoms (SANDE) Questionnaire Scores at Day 28±4 (End of Treatment)
The SANDE (Symptom Assessment in Dry Eye) questionnaire was used to evaluate both dry eye frequency and severity using a 100 mm VAS line, representing ocular dryness and/or irritation at subject's level, according to their own perception, irrespective of the eye being or not the study eye, as per study Protocol. SANDE scores ranged from 0 (best condition) to 100 (worst condition) for both severity and frequency. The VAS score was determined - in millimeters - by measuring from the left-hand end to the marked point on the VAS line. SANDE OVERALL VAS score was calculated considering the mean and the SD of the "Change from Baseline" values at Day 14±2, Day 28±4 and Day 31-41, both for frequency and severity, and then calculated as square-root of the product of the two item score. Results are reported at the patient level, rather than focusing on a single eye, as the SANDE score assesses overall dry eye symptoms rather than eye-specific effects, as per study protocol.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Treatment-emergent Adverse Events (TEAEs), Including Adverse Device Effects (ADEs)
Occurrence of Treatment-emergent adverse events (TEAEs), including adverse device effects (ADEs) assessed throughout the study after the first IMD administration.
Time frame: From Visit 2 (Day 1)" i.e., the day of the first IMD administration to Visit 5 - Final visit/Follow up - Day 31- 41
Changes From Baseline (Visit 2, Day 1) in Ocular Tolerability Using a Visual Analogue Scale (VAS)
A global ocular tolerability score was determined using a 100 mm Visual Analogue Scale (VAS) on which 0 meant no symptoms and 100 meant the worst possible discomfort. This evaluation was to be performed before any ophthalmic assessment at each scheduled visit. Specific ocular symptoms measured with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia. The patients evaluated their symptoms using the VAS giving the value they were feeling from none to an extreme value. The VAS scale was a straight horizontal line of fixed length (100 mm). The ends were defined as extreme limits of the parameter.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Tear Film Osmolarity
Tear film osmolarity as a marker of tear film solute content was performed with a TearLab Osmolarity System. The concentration of the tears was assessed in both eyes before the instillation of any dilating or anaesthetic drops. The tear fluid was collected onto the bottom tip of the test card by passive capillary action. After a successful tear collection, the Pen was docked into the Reader, which showed the quantitative tear film osmolarity result in mOsm/L on the liquid crystal display. Normal Patients: 275-316 mOsms/L (mean 302 mOsms/L), Dry Eye Disease Patients: \> 316 mOsms/L. The higher the score the worst the outcome.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Best Corrected Distance Visual Acuity (BCDVA) - ETDRS Score
Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Permanence of Lubricin on the Ocular Surface - Tear Film Break-up Time (TFBUT)
TFBUT was measured by determining the time to tear break-up. The TFBUT test was performed after instillation of 5 μl of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. With the aid of a slit lamp at 10X magnification using cobalt blue illumination, the examiner monitored the integrity of the tear film, noting the time it took to form lacunae (clear spaces in the tear film) from the time that the eye was opened after the last blink. This measurement was performed within 10 seconds maximum. The TFBUT was measured twice during the first minute after the instillation of the fluorescein. If the 2 readings differed by more than 2 seconds, a third reading was taken. The TFBUT value was the average of the 2 or 3 measurements. Generally, a TFBUT value of 10-35 seconds was considered normal. A value of less than 10 seconds was usually suspicious and may indicate tear film instability. The higher the value, the better the outcome.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Slit Lamp Examination (SLE) Values
The Slit Lamp Examination was used to examine the structures of the eye (eyelids, lashes, conjunctiva, cornea, lens, iris and anterior chamber) according to different scales: Eyelid - Meibomian glands (from 0-none to 3-severe), Eyelid - Erythema (from 0-none to 4-very severe), Eyelid - Oedema (from 0-none to 4-very severe), Lashes (0-normal 1-abnormal), Conjunctiva - Erythema (from 0-none to 3-severe), Conjunctiva - Oedema (from 0-none to 4-very severe), Lens (to 0-no opacification to 3-severe opacification), Iris (0-normal 1-abnormal), Anterior chamber inflammation (from 0-none to 3-severe), Cornea transparency (from 0-completely transparent to 4-complete cornea opacity), Cornea neovascularization (0-absence of vascularization to 4- neovascularization between 270° and 360°). The higher the score the worse the outcome. There was not a total score.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Corneal Fluorescein Surface Staining (Oxford Score)
The corneal fluorescein staining was graded by using the Oxford scheme to assess cornea and conjunctiva epithelium damage. The Oxford grading scale divides corneal staining into six groups according to severity from 0 (absent) to 5 (severe). The examiner compared the overall appearance of the patient's corneal staining with a reference figure, simulating the pattern of staining encountered in dry eye disease. No attempt was made to count the dots or to assess the position or confluence of the dots. The examiner selected the appropriate grade that best represented the state of corneal staining. The grading system recommended by NEI divides the cornea into five zones (central, superior, temporal, nasal, and inferior) and for each zone, the severity of corneal fluorescein staining is graded on a scale from 0 to 3 based on reference figures. Therefore, the maximum score (worst outcome) was 15, the minimum (best outcome) was 0.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Schirmer's Test Type I (Without Anaesthesia)
The Schirmer test Type I (without anaesthesia) was performed to measure aqueous tear secretion prior to the instillation of any dilating or anaesthetic eye drops. The rounded bent end of a sterile strip was inserted into the lower conjunctival sac over the temporal one-third of the lower eyelid margin. After 5 minutes had elapsed, the Schimer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). The longer the wetted length, the healthier the status of the eye.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Change From Baseline in Intraocular Pressure (IOP)
The IOP (intraocular pressure) of the eye was determined by the balance between the amount of aqueous humor that the eye marked and ease with which it leaved the eye. IOP was performed using Goldmann applanation tonometry after the instillation of a topical anaesthetic. The Goldmann applanation tonometer measured the force necessary to flatten a corneal area of 3.06 mm diameter. At this diameter, the resistance of the cornea to flattening was counterbalanced by the capillary attraction of the tear film meniscus for the tonometer head. The IOP (in mm Hg) equals the flattening force (in grams) multiplied by 10. IOP was measured in both eyes after completion of all SLEs to avoid potential interference with the other evaluations. Both eyes were tested. Normal eye pressure was between 10 to 21 mmHg. High ocular pressure was greater than 21 mmHg.
Time frame: Visit 3 - Day 14±2, Visit 4 - Day 28±4, Visit 5 - Final visit/Follow up - Day 31- 41
Recruitment was competitive between the study sites and continued until the planned number of randomised patients was achieved. Competitive recruitment was chosen to increase the speed of recruitment and to account for any difference in enrolment rate between study sites.
| Milestone | Lubricin | OcuYal® |
|---|---|---|
| Started | 27 | 29 |
| Per-protocol population (pp) | 24 | 27 |
| Completed | 26 | 29 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The SANDE (Symptom Assessment in Dry Eye) questionnaire was used to evaluate both dry eye frequency and severity using a 100 mm VAS line, representing ocular dryness and/or irritation at subject's level, according to their own perception, irrespective of the eye being or not the study eye, as per study Protocol. SANDE scores ranged from 0 (best condition) to 100 (worst condition) for both severity and frequency. The VAS score was determined - in millimeters - by measuring from the left-hand end to the marked point on the VAS line. SANDE OVERALL VAS score was calculated considering the mean and the SD of the "Change from Baseline" values at Day 14±2, Day 28±4 and Day 31-41, both for frequency and severity, and then calculated as square-root of the product of the two item score. Results are reported at the patient level, rather than focusing on a single eye, as the SANDE score assesses overall dry eye symptoms rather than eye-specific effects, as per study protocol.
| mm | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Frequency | -11.9 ± 8.6 | -16.6 ± 14.9 |
| Day 28±4 -Frequency | -25.0 ± 12.2 | -26.5 ± 18.0 |
| Day 31-41 - Frequency | -27.8 ± 14.5 | -30.9 ± 19.2 |
| Day 14±2 - Severity | -10.6 ± 6.0 | -13.7 ± 12.8 |
| Day 28±4 - Severity | -22.2 ± 14.1 | -21.8 ± 14.1 |
| Day 31-41 - Severity | -25.6 ± 16.6 | -25.4 ± 14.5 |
| Day 14±2 - Overall Score | -11.2 ± 6.9 | -15.3 ± 13.6 |
| Day 28±4 - Overall score | -23.5 ± 11.9 | -24.2 ± 15.7 |
| Day 31-41 - Overall Score | -26.6 ± 13.4 | -28.3 ± 16.5 |
Occurrence of Treatment-emergent adverse events (TEAEs), including adverse device effects (ADEs) assessed throughout the study after the first IMD administration.
| Number of adverse events | Lubricin SAF | Sodium Hyaluronate SAF |
|---|---|---|
| All TEAEs | 4 | 6 |
| TEAEs - Related to Treatment | 4 | 0 |
| TEAEs - Not Related to Treatment | 0 | 6 |
| TEAEs - Unknown | 0 | 5 |
| TEAEs - Mild | 0 | 0 |
| TEAEs - Moderate | 4 | 1 |
| TEAEs - Severe | 0 | 0 |
| All serious TEAEs | 0 | 0 |
| TEAEs - Leading to discontinuation | 4 | 0 |
A global ocular tolerability score was determined using a 100 mm Visual Analogue Scale (VAS) on which 0 meant no symptoms and 100 meant the worst possible discomfort. This evaluation was to be performed before any ophthalmic assessment at each scheduled visit. Specific ocular symptoms measured with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia. The patients evaluated their symptoms using the VAS giving the value they were feeling from none to an extreme value. The VAS scale was a straight horizontal line of fixed length (100 mm). The ends were defined as extreme limits of the parameter.
| mm | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Foreign Body sensation - Study eye -Day 14±2 | -12.6 ± 11.4 | -16.2 ± 15.4 |
| Foreign Body sensation - Non Study eye -Day 14±2 | -9.4 ± 10.8 | -11.7 ± 10.4 |
| Burning /Stinging - Study eye - Day 14±2 | -15.9 ± 13.5 | -15.7 ± 17.2 |
| Burning /Stinging - Non Study eye - Day 14±2 | -8.9 ± 12.1 | -8.6 ± 10.1 |
| Itching - Study eye - Day 14±2 | -15.7 ± 12.7 | -10.9 ± 15.0 |
| Itching - Non Study eye - Day 14±2 | -10.9 ± 15.7 | -8.9 ± 12.6 |
| Pain - Study eye - Day 14±2 | -13.7 ± 13.0 | -14.2 ± 17.3 |
| Pain - Non Study eye - Day 14±2 | -8.2 ± 12.8 | -10.7 ± 11.0 |
| Sticky feeling- Study eye - Day 14±2 | -13.5 ± 12.5 | -5.6 ± 15.0 |
| Sticky feeling- Non Study eye - Day 14±2 | -11.2 ± 9.8 | -5.7 ± 12.2 |
| Blurred vision- Study eye - Day 14±2 | -11.3 ± 16.1 | -12.0 ± 15.3 |
| Blurred vision- Non Study eye - Day 14±2 | -9.1 ± 14.5 | -5.7 ± 12.0 |
| Photophobia - Study eye - Day 14±2 | -19.5 ± 17.3 | -18.5 ± 17.5 |
| Photophobia - Non Study eye - Day 14±2 | -11.7 ± 13.4 | -19.5 ± 20.9 |
| Total score - Study eye - Day 14±2 | -102.2 ± 64.2 | -93.2 ± 74.3 |
| Total score - Non Study eye - Day 14±2 | -69.5 ± 48.9 | -70.9 ± 56.3 |
| Foreign Body sensation - Study eye -Day 28±4 | -25.0 ± 17.6 | -26.7 ± 19.8 |
| Foreign Body sensation - Non Study eye -Day 28±4 | -17.0 ± 17.3 | -21.8 ± 12.1 |
| Burning /Stinging - Study eye - Day 28±4 | -27.6 ± 18.36 | -23.0 ± 20.0 |
| Burning /Stinging - Non Study eye - Day 28±4 | -14.6 ± 16.3 | -12.3 ± 15.6 |
| Itching - Study eye - Day 28±4 | -27.6 ± 18.5 | -18.5 ± 17.3 |
| Itching - Non Study eye - Day 28±4 | -19.3 ± 16.8 | -15.1 ± 16.2 |
| Pain - Study eye - Day 28±4 | -24.1 ± 18.4 | -20.1 ± 18.4 |
| Pain - Non Study eye - Day 28±4 | -15.0 ± 18.8 | -14.5 ± 15.3 |
| Sticky feeling- Study eye - Day 28±4 | -21.9 ± 18.6 | -13.1 ± 21.5 |
| Sticky feeling - Non Study eye - Day 28±4 | -17.6 ± 19.4 | -9.2 ± 18.0 |
| Blurred vision - Study eye - Day 28±4 | -14.0 ± 19.4 | -15.6 ± 24.5 |
| Blurred vision - Non Study eye - Day 28±4 | -13.4 ± 18.6 | -8.8 ± 19.0 |
| Photophobia - Study eye - Day 28±4 | -28.8 ± 25.1 | -26.1 ± 23.4 |
| Photophobia - Non Study eye - Day 28±4 | -17.1 ± 27.1 | -23.3 ± 26.2 |
| Total score - Study eye - Day 28±4 | -168.9 ± 82.8 | -143.1 ± 107.5 |
| Total score - Non Study eye - Day 28±4 | -114.1 ± 74.3 | -105.0 ± 75.9 |
| Foreign Body sensation - Study eye - Day 31-41 | -28.3 ± 21.8 | -28.1 ± 18.2 |
| Foreign Body sensation - Non study eye - Day 31-41 | -19.7 ± 15.8 | -18.4 ± 14.2 |
| Burning/Stinging -Study eye -Day 31-41 | -30.5 ± 23.5 | -23.6 ± 20.2 |
| Burning/Stinging - Non study eye - Day 31-41 | -11.1 ± 19.2 | -14.1 ± 18.6 |
| Itching - Study eye - Day 31-41 | -28.6 ± 22.9 | -19.1 ± 21.4 |
| Itching - Non study eye - Day 31-41 | -18.9 ± 17.5 | -15.7 ± 21.4 |
| Pain - Study eye - Day 31-41 | -26.9 ± 20.1 | -20.7 ± 18.0 |
| Pain - Non study eye - Day 31-41 | -12.0 ± 21.7 | -18.6 ± 19.4 |
| Sticky feeling - Study eye - Day 31-41 | -20.5 ± 23.1 | -13.3 ± 19.4 |
| Sticky feeling - Non study eye - Day 31-41 | -21.4 ± 21.8 | -5.2 ± 16.3 |
| Blurred vision - Study eye - Day 31-41 | -14.6 ± 19.4 | -15.3 ± 23.9 |
| Blurred vision - Non study eye - Day 31-41 | -10.9 ± 19.8 | -9.8 ± 18.7 |
| Photophobia - Study eye - Day 31-41 | -25.3 ± 25.1 | -24.9 ± 26.0 |
| Photophobia - Non study eye - Day 31-41 | -17.6 ± 27.5 | -19.9 ± 26.6 |
| Total score - Study eye - Day 31-41 | -174.8 ± 96.0 | -145.1 ± 102.2 |
| Total score - Non study eye - Day 31-41 | -11.5 ± 86.2 | -101.4 ± 95.8 |
Tear film osmolarity as a marker of tear film solute content was performed with a TearLab Osmolarity System. The concentration of the tears was assessed in both eyes before the instillation of any dilating or anaesthetic drops. The tear fluid was collected onto the bottom tip of the test card by passive capillary action. After a successful tear collection, the Pen was docked into the Reader, which showed the quantitative tear film osmolarity result in mOsm/L on the liquid crystal display. Normal Patients: 275-316 mOsms/L (mean 302 mOsms/L), Dry Eye Disease Patients: \> 316 mOsms/L. The higher the score the worst the outcome.
| mOsm /L | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | -9.6 ± 15.0 | -12.7 ± 11.8 |
| Day 14±2 - Non Study eye | -10.3 ± 8.4 | -12.1 ± 11.5 |
| Day 28±4 - Study eye | -7.0 ± 24.4 | -12.4 ± 11.3 |
| Day 28±4 - Non study eye | -10.8 ± 11.4 | -12.7 ± 13.0 |
| Day 31-41 - Study eye | -7.6 ± 14.4 | -9.2 ± 10.2 |
| Day 31-41 - Non study eye | -7.8 ± 8.0 | -11.2 ± 11.5 |
Best corrected visual acuity (BCDVA) was determined by careful refraction according to the standard protocol for refraction. Chart 1 was used for testing the VA of the right eye; Chart 2 for the left eye; and Chart R for refraction only. Retroilluminated standard Early Treatment of Diabetic Retinopathy Study (ETDRS) charts were used. They had 5 Sloan letters on each line of equal difficulty, and there was a geometric progression in letter size from line to line. VAS awarded one point for every letter correctly guessed. A distance of 4 meters was required between the subject's eyes and the VA chart. When a subject cannot read at least 20 letters on the chart at 4 meters, the subject was tested at 1 meter. If 20 or more letters were read at 4 meters, the VAS for that eye was recorded as the number of letters correct at 4 meters plus 30. Otherwise, the VAS was the number of letters read correctly at 1 meter plus the number read at 4 meters. The higher the score the better the outcome.
| score on a scale | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | 0.0 ± 1.2 | -0.1 ± 1.0 |
| Day 14±2 -Non study eye | -0.2 ± 0.8 | -0.3 ± 1.3 |
| Day 28±4 - Study eye | 0.0 ± 1.6 | -0.3 ± 1.5 |
| Day 28±4 - Non study eye | 0.0 ± 1.2 | -0.4 ± 1.8 |
| Day 31-41 - Study eye | 0.1 ± 1.8 | -0.2 ± 1.9 |
| Day 31-41 - Non study eye | -0.3 ± 1.3 | -0.5 ± 1.8 |
TFBUT was measured by determining the time to tear break-up. The TFBUT test was performed after instillation of 5 μl of 2% preservative-free sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. With the aid of a slit lamp at 10X magnification using cobalt blue illumination, the examiner monitored the integrity of the tear film, noting the time it took to form lacunae (clear spaces in the tear film) from the time that the eye was opened after the last blink. This measurement was performed within 10 seconds maximum. The TFBUT was measured twice during the first minute after the instillation of the fluorescein. If the 2 readings differed by more than 2 seconds, a third reading was taken. The TFBUT value was the average of the 2 or 3 measurements. Generally, a TFBUT value of 10-35 seconds was considered normal. A value of less than 10 seconds was usually suspicious and may indicate tear film instability. The higher the value, the better the outcome.
| seconds | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | 1.0 ± 2.0 | 1.1 ± 2.5 |
| Day 14±2 - Non study eye | 0.6 ± 2.7 | 1.6 ± 2.6 |
| Day 28±4 - Study eye | 1.3 ± 2.1 | 1.9 ± 2.7 |
| Day 28±4 - Non study eye | 0.3 ± 2.8 | 2.5 ± 2.8 |
| Day 31-41 - Study eye | 0.5 ± 1.8 | 1.0 ± 1.8 |
| Day 31-41 - Non study eye | 0.5 ± 2.5 | 1.4 ± 2.0 |
The Slit Lamp Examination was used to examine the structures of the eye (eyelids, lashes, conjunctiva, cornea, lens, iris and anterior chamber) according to different scales: Eyelid - Meibomian glands (from 0-none to 3-severe), Eyelid - Erythema (from 0-none to 4-very severe), Eyelid - Oedema (from 0-none to 4-very severe), Lashes (0-normal 1-abnormal), Conjunctiva - Erythema (from 0-none to 3-severe), Conjunctiva - Oedema (from 0-none to 4-very severe), Lens (to 0-no opacification to 3-severe opacification), Iris (0-normal 1-abnormal), Anterior chamber inflammation (from 0-none to 3-severe), Cornea transparency (from 0-completely transparent to 4-complete cornea opacity), Cornea neovascularization (0-absence of vascularization to 4- neovascularization between 270° and 360°). The higher the score the worse the outcome. There was not a total score.
| score on a scale | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Eyelid - Meibomian gland - Study eye - Day 14±2 | -0.5 ± 0.6 | -0.4 ± 0.5 |
| Eyelid - Meibomian gland - Non study eye - Day 14±2 | -0.5 ± 0.6 | -0.4 ± 0.6 |
| Eyelid - Erythema - Study eye - Day 14±2 | -0.3 ± 0.6 | -0.4 ± 0.7 |
| Eyelid - Erythema - Non study eye - Day 14±2 | -0.2 ± 0.6 | -0.4 ± 0.7 |
| Eyelid - Oedema - Study eye - Day 14±2 | -0.2 ± 0.5 | -0.1 ± 0.6 |
| Eyelid - Oedema - Non study eye - Day 14±2 | -0.2 ± 0.4 | -0.1 ± 0.5 |
| Lashes - Study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Lashes - Non study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Conjunctiva - Erythema - Study eye - Day 14±2 | -0.4 ± 0.6 | -0.4 ± 0.7 |
| Conjunctiva - Erythema - Non study eye - Day 14±2 | -0.3 ± 0.6 | -0.4 ± 0.8 |
| Conjunctiva - Oedema - Study eye - Day 14±2 | 0.0 ± 0.5 | -0.1 ± 0.7 |
| Conjunctiva - Oedema - Non study eye - Day 14±2 | -0.1 ± 0.5 | -0.1 ± 0.6 |
| Lens - Study eye - Day 14±2 | 0.0 ± 0.2 | 0.0 ± 0.3 |
| Lens - Non study eye - Day 14±2 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Iris - Study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Iris - Non study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Non study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea transparency - Study eye - Day 14±2 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Cornea transparency - Non study eye - Day 14±2 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Cornea neovascularisation - Study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea neovascularisation - Non study eye - Day 14±2 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Eyelid - Meibomian gland - Study eye - Day 28±4 | -0.5 ± 0.7 | -0.7 ± 0.7 |
| Eyelid - Meibomian gland - Non study eye -Day 28±4 | -0.5 ± 0.8 | -0.6 ± 0.7 |
| Eyelid - erythema - Study eye - Day 28±4 | -0.5 ± 0.7 | -0.4 ± 0.8 |
| Eyelid - erythema - Non study eye - Day 28±4 | -0.5 ± 0.9 | -0.4 ± 0.8 |
| Eyelid - Oedema - Study eye - Day 28±4 | -0.3 ± 0.8 | -0.3 ± 0.8 |
| Eyelid - Oedema - Non study eye - Day 28±4 | -0.3 ± 0.7 | -0.2 ± 0.7 |
| Lashes - Study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Lashes - Non study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Conjunctiva - erythema - Study eye - Day 28±4 | -0.6 ± 0.8 | -0.6 ± 0.8 |
| Conjunctiva - erythema - Non study eye - Day 28±4 | -0.4 ± 0.9 | -0.5 ± 0.9 |
| Conjunctiva - Oedema - Study eye - Day 28±4 | -0.2 ± 0.7 | 0.0 ± 0.8 |
| Conjunctiva - Oedema - Non study eye - Day 28±4 | 0.0 ± 0.7 | -0.1 ± 0.8 |
| Lens - Study eye - Day 28±4 | 0.0 ± 0.2 | 0.0 ± 0.3 |
| Lens - Non study eye - Day 28±4 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Iris - Study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Iris - Non study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Non study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea tranparency - Study eye - Day 28±4 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Cornea tranparency - Non study eye - Day 28±4 | 0.0 ± 0.2 | 0.0 ± 0.2 |
| Cornea neovascularization - Study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea neovascularization - Non study eye - Day 28±4 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Eyelid - Meibomian gland - Study eye - Day 31-41 | -0.6 ± 0.8 | -0.9 ± 0.8 |
| Eyelid - Meibomian gland - Non study eye - Day 31-41 | -0.7 ± 0.9 | -0.7 ± 0.8 |
| Eyelid - erythema - Study eye - Day 31-41 | -0.6 ± 0.7 | -0.6 ± 0.8 |
| Eyelid - erythema - Non study eye - Day 31-41 | -0.6 ± 0.9 | -0.4 ± 0.8 |
| Eyelid - Oedema - Study eye - Day 31-41 | -0.4 ± 0.7 | 0.0 ± 0.6 |
| Eyelid - Oedema - Non study eye - Day 31-41 | -0.3 ± 0.9 | 0.0 ± 0.6 |
| Lashes - Study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Lashes - Non study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Conjunctiva - erythema - Study eye - Day 31-41 | -0.8 ± 1.0 | -0.4 ± 1.0 |
| Conjunctiva - erythema - Non study eye - Day 31-41 | -0.5 ± 1.0 | -0.4 ± 0.9 |
| Conjunctiva - Oedema - Study eye - Day 31-41 | -0.1 ± 0.9 | 0.0 ± 0.9 |
| Conjunctiva - Oedema - Non study eye - Day 31-41 | 0.0 ± 0.8 | -0.1 ± 0.9 |
| Lens - Study eye - Day 31-41 | 0.0 ± 0.2 | 0.0 ± 0.4 |
| Lens - Non study eye - Day 31-41 | 0.0 ± 0.2 | -0.1 ± 0.3 |
| Iris - Study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Iris - Non study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Anterior chamber inflammation - Non study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea transparency - Study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.2 |
| Cornea transparency - Non study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.2 |
| Cornea neovascularization - Study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Cornea neovascularization - Non study eye - Day 31-41 | 0.0 ± 0.0 | 0.0 ± 0.0 |
The corneal fluorescein staining was graded by using the Oxford scheme to assess cornea and conjunctiva epithelium damage. The Oxford grading scale divides corneal staining into six groups according to severity from 0 (absent) to 5 (severe). The examiner compared the overall appearance of the patient's corneal staining with a reference figure, simulating the pattern of staining encountered in dry eye disease. No attempt was made to count the dots or to assess the position or confluence of the dots. The examiner selected the appropriate grade that best represented the state of corneal staining. The grading system recommended by NEI divides the cornea into five zones (central, superior, temporal, nasal, and inferior) and for each zone, the severity of corneal fluorescein staining is graded on a scale from 0 to 3 based on reference figures. Therefore, the maximum score (worst outcome) was 15, the minimum (best outcome) was 0.
| score on a scale | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | -0.3 ± 0.4 | -0.4 ± 0.6 |
| Day 14±2 - Non study eye | -0.3 ± 0.5 | -0.5 ± 0.8 |
| Day 28±4 - Study eye | -0.9 ± 0.9 | -0.8 ± 0.9 |
| Day 28±4 - Non study eye | -0.7 ± 0.6 | -0.7 ± 0.9 |
| Day 31-41 - Study eye | -1.0 ± 0.9 | -1.0 ± 0.9 |
| Day 31-41 - Non study eye | -1.0 ± 0.9 | -0.7 ± 1.0 |
The Schirmer test Type I (without anaesthesia) was performed to measure aqueous tear secretion prior to the instillation of any dilating or anaesthetic eye drops. The rounded bent end of a sterile strip was inserted into the lower conjunctival sac over the temporal one-third of the lower eyelid margin. After 5 minutes had elapsed, the Schimer's test strip was removed and the length of the tear absorption on the strip was measured (millimeters/5 minutes). The longer the wetted length, the healthier the status of the eye.
| mm/5min | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | 0.7 ± 2.4 | 1.0 ± 2.8 |
| Day 14±2 - Non study eye | 0.9 ± 2.5 | 1.5 ± 3.1 |
| Day 28±4 - Study eye | 1.2 ± 3.6 | 0.9 ± 2.5 |
| Day 28±4 - Non study eye | 1.1 ± 3.2 | 1.5 ± 2.6 |
| Day 31-41 - Study eye | 0.5 ± 1.9 | 0.3 ± 2.0 |
| Day 31-41 - Non study eye | 0.4 ± 1.6 | 0.7 ± 2.3 |
The IOP (intraocular pressure) of the eye was determined by the balance between the amount of aqueous humor that the eye marked and ease with which it leaved the eye. IOP was performed using Goldmann applanation tonometry after the instillation of a topical anaesthetic. The Goldmann applanation tonometer measured the force necessary to flatten a corneal area of 3.06 mm diameter. At this diameter, the resistance of the cornea to flattening was counterbalanced by the capillary attraction of the tear film meniscus for the tonometer head. The IOP (in mm Hg) equals the flattening force (in grams) multiplied by 10. IOP was measured in both eyes after completion of all SLEs to avoid potential interference with the other evaluations. Both eyes were tested. Normal eye pressure was between 10 to 21 mmHg. High ocular pressure was greater than 21 mmHg.
| mmHg | Lubricin PP | Sodium Hyaluronate PP |
|---|---|---|
| Day 14±2 - Study eye | 0.7 ± 1.9 | -0.6 ± 2.1 |
| Day 14±2 - Non study eye | -0.4 ± 2.1 | -0.2 ± 1.9 |
| Day 28±4 - Study eye | -0.2 ± 1.8 | -0.4 ± 2.5 |
| Day 28±4 - Non study eye | -0.3 ± 1.7 | 0.1 ± 2.6 |
| Day 31-41 - Study eye | -0.8 ± 2.6 | -0.9 ± 2.5 |
| Day 31-41 - Non study eye | -0.5 ± 2.5 | -0.2 ± 2.6 |
Collected over AEs were assessed throughout the clinical investigation (V1 at Day -14 - -8; V2 at Day 1; V3 at Day 14 ± 2; V4 at Day 28 ± 4) up to final visit, at day 31- 41 (V5).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lubricin SAF | 0/27 (0%) | 0/27 (0%) | 1/27 (3.7%) |
| Sodium Hyaluronate SAF | 0/29 (0%) | 0/29 (0%) | 2/29 (6.9%) |
| Event | Lubricin SAF | Sodium Hyaluronate SAF |
|---|---|---|
| Eye irritationEye disorders | 1/27 | 0/29 |
| Eye oedemaEye disorders | 1/27 | 0/29 |
| Lacrimation increasedEye disorders | 1/27 | 0/29 |
| Vision blurredEye disorders | 1/27 | 0/29 |
| Dry eyeEye disorders | 0/27 | 1/29 |
| Foreign body sensation in eyesEye disorders | 0/27 | 1/29 |
| Staphylococcal infectionInfections and infestations | 0/27 | 1/29 |
Per Protocol set (PP): all enrolled subjects who fulfilled the investigation protocol requirements in terms of IMD intake (Lubricin or OcuYal®) during the treatment phase and collection of primary efficacy data and with no major deviations that could affect the results. This analysis set was used for the efficacy analysis.
| Age, Categorical(Participants) | Lubricin | Sodium Hyaluronate | Total |
|---|---|---|---|
| PP population — <=18 years | 0 | 0 | 0 |
| PP population — Between 18 and 65 years | 18 | 17 | 35 |
| PP population — >=65 years | 6 | 10 | 16 |
| Age, Continuous(years) | Lubricin | Sodium Hyaluronate | Total |
|---|---|---|---|
| PP population | 57.6 ± 10.6 | 57.7 ± 12.9 | 57.7 ± 11.7 |
| Sex: Female, Male(Participants) | Lubricin | Sodium Hyaluronate | Total |
|---|---|---|---|
| PP population — Female | 18 | 24 | 42 |
| PP population — Male | 6 | 3 | 9 |
| Race (NIH/OMB)(Participants) | Lubricin | Sodium Hyaluronate | Total |
|---|---|---|---|
| PP population — American Indian or Alaska Native | 0 | 0 | 0 |
| PP population — Asian | 0 | 0 | 0 |
| PP population — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| PP population — Black or African American | 0 | 0 | 0 |
| PP population — White | 24 | 27 | 51 |
| PP population — More than one race | 0 | 0 | 0 |
| PP population — Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Lubricin | Sodium Hyaluronate | Total |
|---|---|---|---|
| Italy | 24 | 27 | 56 |
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dompé Farmaceutici S.p.A